A phase 3 win should remind investors about other clinical-stage CXCR4 antagonists.
The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.
A US advisory panel has largely endorsed three anti-PD-(L)1 drugs, with voting apparently driven by the availability of alternatives.
Planning for this week’s three-day adcom on US accelerated approvals for anti-PD-(L)1 drugs? Here’s the background info you need.
A pivotal win puts nirsevimab on track to be filed next year, but the reimbursement hurdle looms.
Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.